These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 29217104)

  • 21. How beneficial and safe is tocilizumab for patients with giant cell arteritis? A Cochrane Review summary with commentary.
    Coskun Benlidayi I
    Int J Rheum Dis; 2022 Aug; 25(8):945-949. PubMed ID: 35796249
    [No Abstract]   [Full Text] [Related]  

  • 22. Treatment failure in giant cell arteritis.
    Unizony SH; Bao M; Han J; Luder Y; Pavlov A; Stone JH
    Ann Rheum Dis; 2021 Nov; 80(11):1467-1474. PubMed ID: 34049857
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tocilizumab in Giant Cell Arteritis: A Real-Life Retrospective Study.
    Vitiello G; Orsi Battaglini C; Carli G; Radice A; Matucci A; Vultaggio A; Olianti C; Parronchi P; Maggi E; Cammelli D
    Angiology; 2018 Oct; 69(9):763-769. PubMed ID: 29343075
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcomes of giant cell arteritis patients treated with tocilizumab in a single neuro-ophthalmology practice.
    Fong JW; Sharieff JA; Patel AD
    Can J Ophthalmol; 2023 Apr; 58(2):e61-e62. PubMed ID: 36126697
    [No Abstract]   [Full Text] [Related]  

  • 25. Giant Cell Arteritis: Beyond Corticosteroids.
    Steel L; Khan A; Dasgupta B
    Drugs Aging; 2015 Aug; 32(8):591-9. PubMed ID: 26239828
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantitative ultrasound to monitor the vascular response to tocilizumab in giant cell arteritis.
    Seitz L; Christ L; Lötscher F; Scholz G; Sarbu AC; Bütikofer L; Kollert F; Schmidt WA; Reichenbach S; Villiger PM
    Rheumatology (Oxford); 2021 Nov; 60(11):5052-5059. PubMed ID: 34117737
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reply to Should Tocilizumab Be Used Routinely in New Patients With a Diagnosis of Giant Cell Arteritis?
    Gordon LK; Sadun AA; Van Stavern G; Lee AG
    J Neuroophthalmol; 2022 Jun; 42(2):e535-e536. PubMed ID: 35594160
    [No Abstract]   [Full Text] [Related]  

  • 28. Tocilizumab-induced sarcoidosis-like reaction in a patient with giant cell arteritis. Clinical implications of a paradoxical phenomenon.
    Theodosiou G; Luu H; Svensson Å
    Int J Dermatol; 2020 Jul; 59(7):888-889. PubMed ID: 32358964
    [No Abstract]   [Full Text] [Related]  

  • 29. Tocilizumab in the treatment of giant cell arteritis.
    Leuchten N; Aringer M
    Immunotherapy; 2018 Mar; 10(6):465-472. PubMed ID: 29504436
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tocilizumab in giant cell arteritis: an update for the clinician.
    Ford JA; Gewurz D; Gewurz-Singer O
    Curr Opin Rheumatol; 2023 May; 35(3):135-140. PubMed ID: 36912060
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immuno-monitoring reveals an extended subclinical disease activity in tocilizumab-treated giant cell arteritis.
    Gloor AD; Yerly D; Adler S; Reichenbach S; Kuchen S; Seitz M; Villiger PM
    Rheumatology (Oxford); 2018 Oct; 57(10):1795-1801. PubMed ID: 29961816
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tocilizumab as an add-on therapy to glucocorticoids during the first 3 months of treatment of Giant cell arteritis: A prospective study.
    Samson M; Devilliers H; Ly KH; Maurier F; Bienvenu B; Terrier B; Charles P; Guillevin L; Besancenot JF; Liozon E; Fauchais AL; Loffroy R; Binquet C; Audia S; Seror R; Mariette X; Bonnotte B
    Eur J Intern Med; 2018 Nov; 57():96-104. PubMed ID: 30054122
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tocilizumab for Giant Cell Arteritis-A New Giant Step in an Old Disease.
    Tamaki H; Hajj-Ali RA
    JAMA Neurol; 2018 Feb; 75(2):145-146. PubMed ID: 29255889
    [No Abstract]   [Full Text] [Related]  

  • 34. [Treatment of giant cell arteritis].
    Samson M; Greigert H; Ghesquière T; Bonnotte B
    Presse Med; 2019 Sep; 48(9):968-979. PubMed ID: 31324351
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interleukin-6 flags infection in tocilizumab-treated giant cell arteritis.
    Berger CT; Recher M; Daikeler T
    Rheumatology (Oxford); 2018 Jan; 57(1):196-197. PubMed ID: 28968856
    [No Abstract]   [Full Text] [Related]  

  • 36. The Role of Tocilizumab in Glucocorticoid Resistant Giant Cell Arteritis: A Case Series and Literature Review.
    Stretton B; Tan Y; Hassall M; Simon S
    J Neuroophthalmol; 2023 Mar; 43(1):91-95. PubMed ID: 36166708
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successful use of ixekizumab for glucocorticoid-free remission maintenance in giant cell arteritis.
    Tomelleri A; Rinaldi E; Campochiaro C; Picchio M; Dagna L
    Rheumatology (Oxford); 2023 Feb; 62(2):e24-e26. PubMed ID: 35861513
    [No Abstract]   [Full Text] [Related]  

  • 38. [Treatment of giant cell arteritis: what is in the pipeline?].
    Holle JU; Moosig F
    Z Rheumatol; 2020 Aug; 79(6):516-522. PubMed ID: 32399619
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A severe cerebral infarction associated with giant cell arteritis, which developed during tocilizumab therapy and was successfully treated with intravenous cyclophosphamide.
    Suzuki K; Akiyama M; Ishigaki S; Kondo Y; Saito S; Kikuchi J; Hanaoka H; Kaneko Y
    Mod Rheumatol Case Rep; 2023 Jun; 7(2):453-457. PubMed ID: 36715093
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A multicentre, large-scale, observational study of tocilizumab in patients with giant cell arteritis in Japan.
    Harigai M; Miyamae T; Hashimoto H; Umetsu K; Yamashita K; Nakaoka Y
    Mod Rheumatol; 2024 Jul; 34(4):775-783. PubMed ID: 37522620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.